Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VACV tablets (Adults or pediatrics) or granules (pediatrics)
VACV or granules · 1 trial · 1 indication
Viral isolation/identification was conducted if the investigator (or subinvestigator) suspected HSV infection according to the relevant clinical symptoms (oral mucositis, skin infection, genital herpes, and pneumonia). If the result of viral isolation/identification was positive, the participant concerned was defined as a case of HSV infection. For reference, a virus deoxyribonucleic acid (DNA) identification (PCR) was simultaneously performed.
| Arm | Type | Description |
|---|---|---|
| VACV (256U87; valaciclovir hydrochloride) | EXPERIMENTAL | Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily. |
| Name | Type | Description |
|---|---|---|
| VACV tablets (Adults or pediatrics) or granules (pediatrics) | DRUG | A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor. |
Inclusion Criteria: * Patients who are planning to undergo hematopoietic stem cell transplantation, except cord blood transplantation. * Patients aged from 1 and above to under 65 at the time of informed consent. * Patients who can submit their voluntary written informed consent if they are 12 year...